Selectively enhanced radiation sensitivity in prostate cancer cells associated with proteasome inhibition

Oncology Reports

Volumn 15, Issue 5, 2006, Pages 1287-1291

  Warren, Graham ^a   Grimes, Kris ^a   Xu, Yong ^b   Kudrimoti, Mahesh ^a   St Clair, William ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Inhibition; MG 132; NF B; PC3; Prostate; Proteasome; Radiation; URO tsa; Urothelial

Indexed keywords

BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CYSTEINE PROTEINASE INHIBITOR; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUPEPTIN; PROTEASOME; RADIOSENSITIZING AGENT;

APOPTOSIS; ARTICLE; CELL CULTURE; CLONOGENIC ASSAY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; RADIATION DOSE; RADIATION EXPOSURE;

APOPTOSIS; COLONY-FORMING UNITS ASSAY; CYSTEINE PROTEINASE INHIBITORS; HUMANS; I-KAPPA B KINASE; LEUPEPTINS; MALE; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED;

EID: 33745003457     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.5.1287     Document Type: Article

References (21)

1. Crawford ED: Epidemiology of prostate cancer. Urology 62: 3-12, 2003.
2. Pajonk F and McBride: WH The proteasome in cancer biology and treatment. Radiation Res 156: 447-459, 2001.
3. Voorhees PM, Dees EC, O'Neil B and Orlowski RZ: The proteasome as a target for cancer therapy. Clin Cancer Res 9: 6316-6325, 2003. (Pubitemid 38031815)
4. Pati S, Pelser CB, Dufraine J, et al: Antitumorigenic effect of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 99: 3771-3779, 2002. (Pubitemid 34534550)
5. Pajonk F, Himmelsbach J, Riess K, et al: The human immunodeficiency virus (HIV)-1 proteasome inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 62: 5230-5235, 2002. (Pubitemid 35024595)
6. Ikezoe T, Daar ES, Hisatake J, et al: HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. Blood 96: 3553-3559, 2000.
7. Hochwald SN, Lind DS, Malaty J, et al: Antineoplastic therapy in colorectal cancer through proteasome inhibition. Am Surg 69: 15-23, 2003.
8. Orlowski RZ and Baldwin AS: NF-κB as a therapeutic target in cancer. Trends Mol Med 8: 385-389, 2002.
9. An J, Sun YP, Adams J, et al: Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res 9: 4537-4545, 2003. (Pubitemid 37248413)
10. Levine L, Lucci JA, Pasdrak B, et al : Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 63: 3495-3502, 2003. (Pubitemid 36793027)
11. Herrmann JL, Briones F, Brisbay S, et al: Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene 17: 2889-2999, 1998.
12. Rossi MR, Masters JR, Park S, et al: The immortilized UROtsa cell line as a potential cell culture model of human urothelium. Environ Health Perspect 109: 801-808, 2001. (Pubitemid 32910302)
13. Cusack JC: Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29: 21-31, 2003.
14. Adams J: The proteasome: structure, function, and role in the cell. Cancer Treat Rev 29: 3-9, 2003.
15. Aggarwal BB: Nuclear factor-kappaB: the enemy within. Cancer Cell 6: 203-208, 2004.
16. Shishodia S and Aggarwal BB: Nuclear factor-kappa B: a friend or foe in cancer? Biochem Pharmacol 68: 1071-1080, 2004. (Pubitemid 39094272)
17. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
18. Pajonk F, Pajonk K and McBride WH: Apoptosis and radio-sensitization of hodgkin cells by proteasome inhibition. Int J Radiat Oncol Biol Phys 47: 1025-1032, 2000. (Pubitemid 30345603)
19. Zerbini LF, Wang Y, Cho JY and Libermann TA: Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 63: 2206-2215, 2003. (Pubitemid 36538628)
20. Li N and Karin M: Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms. Proc Natl Acad Sci USA 95: 1301-1307, 1998.
21. Russell JS and Tofilon PJ: Radiation-induced activation of nuclear factor-kappaB involves selective degradation of plasma membrane-associated I(kappa)B(alpha). Mol Cell Biol 13: 3431-3440, 2002. (Pubitemid 35191365)